Gilead Sciences, Inc.
$25.0 million
2024
License agreement for efarindodekin alfa and stock purchase by Gilead of common stock and prefunded warrants in three private placements
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
License agreement for efarindodekin alfa and stock purchase by Gilead of common stock and prefunded warrants in three private placements
Purchase of prefunded warrants in the April 2024 private placement
Purchase of common stock in the April 2024 private placement
Collaboration, license and option agreement and purchase of 310,559 shares of common stock in a private placement at $32.20 per share
Purchase of prefunded warrants with series A, B and C warrants in the June 2025 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Loading...
